Myt1 激酶:一种新兴的细胞循环调节剂,用于癌症治疗
Fengchao Lang1, Karambir Kaur1, Javeria Zaheer1
1Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
概括
癌细胞依赖G2-M检查点生存,使蛋白质激酶,膜相关的氨酸/氨酸1成为一个有前途的目标. 准这种分子可能会克服治疗耐药性,并阻止癌症的进展.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 细胞生物学 细胞生物学
背景情况:
- 细胞周期检查点对于调节细胞分裂和预防错误至关重要.
- 癌细胞经常利用G2-M检查点进行DNA修复,从而导致治疗耐药性和疾病进展.
- 准G2-M检查点是癌症治疗中验证的策略,临床试验中有几种药物.
研究的目的:
- 审查针对蛋白质激酶,膜相关的氨酸/三氨酸1 (一个关键的G2-M检查点调节器) 的最新进展.
- 讨论针对这种分子在各种癌症类型中的治疗潜力.
- 确定针对蛋白激酶,膜关联型氨酸/三氨酸的临床应用所面临的挑战和局限性 1.
主要方法:
- 对最近的基因组规模功能性基因组学研究的综述.
- 对蛋白激酶,膜相关的氨酸/氨酸的分子向策略的概述 1.
- 对现有临床数据和研究结果的分析.
主要成果:
- 蛋白质激酶,膜相关的氨酸/氨酸1已经成为一个至关重要的,但以前被低估的G2-M检查点组件.
- 这种分子在多种癌症类型中显示出作为治疗点的前景.
- 癌细胞对这个检查点的依赖性造成了可以被利用的脆弱性.
结论:
- 蛋白质激酶,膜相关的氨酸/氨酸1代表了新型癌症治疗的重要目标.
- 需要进一步的研究来克服挑战,并扩大针对这种分子的临床实用性.
- 准这种途径有可能改善G2-M检查点依赖性癌症的治疗结果.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


